Volitionrx LTD 10-Q quarterly reports

VolitionRx Limited reported a significant increase in revenues driven by product sales, but also a wider net loss due to increased operating expenses and non-cash accounting charges.

VolitionRx Limited reported a net loss of $17.2 million for the nine months ended September 30, 2025, while actively raising capital and expanding commercialization efforts for its diagnostic tests.

VolitionRx Limited filed an amended quarterly report to include previously omitted exhibits, notably increasing its 'Capital On Demand' sales agreement to $30 million.

VolitionRx Limited reported a reduced net loss for the first half of 2025, driven by lower operating expenses, while expanding its Nu.Q Vet Cancer Test to 16 countries and securing new financing.

VolitionRx enters into a securities purchase agreement with Lind Global Asset Management for $6.25 million in funding, issuing a convertible note and common stock purchase warrant.

VolitionRx Limited's Q3 2024 results show a significant increase in revenue driven by product sales, particularly the Nu.Q Vet Cancer Test, alongside a reduction in operating expenses.

VolitionRx Limited's second quarter 2024 results show a decrease in net loss and increased revenue, driven by product sales, while the company continues to address material weaknesses in internal controls.

VolitionRx reported a net loss of $8.5 million for the first quarter of 2024, while continuing to advance its commercialization strategy.